Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 610

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

Open access
Kantarjian, Hagop M., Shah, Neil P., Cortes, Jorge E., Baccarani, Michele, Agarwal, Mohan B., Undurraga, María Soledad, Wang, Jianxiang, Kassack Ipiña, Juan Julio, Kim, Dong-Wook, Ogura, Michinori, Pavlovsky, Carolina, Junghanss, Christian, Milone, Jorge H., Nicolini, Franck E., Robak, Tadeusz, Van Droogenbroeck, Jan, Vellenga, Edo, Bradley-Garelik, M. Brigid, Zhu, Chao, Hochhaus, Andreas·2012·Blood

Abstract

Dasatinib is a highly potent BCR-ABL inhibitor with established efficacy and safety in imatinib-resistant/-intolerant patients with chronic myeloid leukemia (CML). In the phase 3 DASISION trial, patients with newly diagnosed chronic-phase (CP) CML were randomized to receive dasatinib 100 mg (n = 259) or imatinib 400 mg (n = 260) once daily. Primary data showed superior efficacy for dasatinib compared with imatinib after 12 months, including significantly higher rates of complete cytogenetic response (CCyR), confirmed CCyR (primary end point), and major molecular response (MMR). Here, 24-month data are presented. Cumulative response rates by 24 months in dasatinib and imatinib arms were: CCyR in 86% versus 82%, MMR in 64% versus 46%, and BCR-ABL reduction to ≤ 0.0032% (4.5-log reduction) in 17% versus 8%. Transformation to accelerated-/ blast-phase CML on study occurred in 2.3% with dasatinib versus 5.0% with imatinib. BCR-ABL mutations, assessed after discontinuation, were detected in 10 patients in each arm. In safety analyses, fluid retention, superficial edema, myalgia, vomiting, and rash were less frequent with dasatinib compared with imatinib, whereas pleural effusion and grade 3/4 thrombocytopenia were more frequent with dasatinib. Overall, dasatinib continues to show faster and deeper responses compared with imatinib, supporting first-line use of dasatinib in patients with newly diagnosed CML-CP. This study was registered at ClinicalTrials.gov: NCT00481247.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-08-376087

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 610

Metadata

Authors
Kantarjian, H. M., Shah, N. P., Cortes, J. E., Baccarani, M., Agarwal, M. B., Undurraga, M. S., Wang, J., Kassack Ipiña, J. J., Kim, D.-W., Ogura, M., Pavlovsky, C., Junghanss, C., Milone, J. H., Nicolini, F. E., Robak, T., Van Droogenbroeck, J., Vellenga, E., Bradley-Garelik, M. B., Zhu, C., & Hochhaus, A.
Venue
Blood
Published
2012-02-02
Volume
119
Issue
5
Pages
1123-1129
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2057206328
Cited by
610
References
2
FWCI
44.14
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). https://app.cochat.ai/papers/10.1182/blood-2011-08-376087
The paper
Kantarjian, H. M., Shah, N. P., Cortes, J. E., Baccarani, M., Agarwal, M. B., Undurraga, M. S., Wang, J., Kassack Ipiña, J. J., Kim, D.-W., Ogura, M., Pavlovsky, C., Junghanss, C., Milone, J. H., Nicolini, F. E., Robak, T., Van Droogenbroeck, J., Vellenga, E., Bradley-Garelik, M. B., Zhu, C., & Hochhaus, A. (2012). Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. https://doi.org/10.1182/blood-2011-08-376087

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.